Document Detail


A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden.
MedLine Citation:
PMID:  11926709     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The objective of this analysis was to calculate the cost-effectiveness of amlodipine therapy in patients with coronary artery disease in Sweden. It is hypothesised that treatment with amlodipine will have an impact on overall cardiovascular disease treatment costs, resulting in a positive cost-effectiveness profile. A Markov cohort simulation model was constructed to simulate event-related and procedure-related health economic outcomes of coronary artery disease populations on amlodipine versus those on placebo. Patient level data from the Prospective Evaluation of the Vascular Effects of Norvasc Trial was used to populate the model. The total number of adverse cardiovascular clinical outcomes experienced over a three-year period was lower for patient on amlodipine than for those on placebo. The rate of hospitalisation per patient due to angina, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, congestive heart failure, and myocardial infarction in the placebo cohort was 64.7%, while the rate in the amlodipine cohort was 46.9%. The cost per patient was Swedish kroner (SEK)26,600 for amlodipine patients and SEK27,400 for placebo patients. The use of amlodipine resulted in improved clinical outcomes as well as a slight savings in cost over a three-year period.
Authors:
J J Doyle; A McGuire; R Arocho; S Arikian; J Casciano; P Svangren; R Casciano; R Kim; H Kugel
Related Documents :
11553909 - Application of excimer laser angioplasty in acute myocardial infarction.
8021049 - Coronary angioplasty for isolated non-dominant left circumflex coronary artery disease.
2251989 - Recanalization of chronic total coronary arterial occlusions by percutaneous excimer-la...
20186239 - Door to balloon times: streamlining admission for primary percutaneous coronary interve...
17452149 - Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patien...
8680269 - High-risk coronary angioplasty assisted by active hemoperfusion. a feasibility study.
9195239 - Multi-purpose mechanical circulatory device.
15729529 - Aetiopathogenesis and long-term outcome of isolated pontine infarcts.
15862409 - Prediction of mortality after primary percutaneous coronary intervention for acute myoc...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of clinical practice     Volume:  56     ISSN:  1368-5031     ISO Abbreviation:  Int. J. Clin. Pract.     Publication Date:  2002 Mar 
Date Detail:
Created Date:  2002-04-02     Completed Date:  2002-04-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9712381     Medline TA:  Int J Clin Pract     Country:  England    
Other Details:
Languages:  eng     Pagination:  76-81     Citation Subset:  IM    
Affiliation:
The Analytica Group, New York, NY 10016, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amlodipine / economics*,  therapeutic use
Analysis of Variance
Calcium Channel Blockers / economics*,  therapeutic use
Cohort Studies
Coronary Artery Disease / drug therapy,  economics*
Cost-Benefit Analysis
Humans
Markov Chains
Models, Econometric
Prospective Studies
Sensitivity and Specificity
Sweden
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bleeding angiodysplasia: should we concentrate more on the aortic valve than on the bowel?
Next Document:  Acceptable agreement between tympanic and rectal temperature in acute stroke patients.